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1  | INTRODUC TION
Hypertension is a major risk factor for cardiovascular diseases such 
as stroke, myocardial infarction (MI), peripheral arterial disease, and 
heart failure.1 Controlling blood pressure (BP) with antihypertensive 
drugs lowers the risk of cardiovascular events and cardiovascular 
mortality.2 However, optimal BP management goals have been con-
troversial in many countries. The Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure (JNC7) guidelines was published in 2003 and sets 
 
Received: 1 June 2020  |  Revised: 4 August 2020  |  Accepted: 22 August 2020
DOI: 10.1111/jch.14034  
O R I G I N A L  P A P E R
Association of optimal blood pressure with mortality in 
patients taking antihypertensive medications
Dong-Ho Yun MD1  |   Hye-Sun Lee PhD2  |   Won-Jun Choi MD1,3  |    
Hyuk-Jae Chang MD, PhD4  |   Da-Hye Son MD1  |   Ji-Won Lee MD, PhD1
Da-Hye Son and Ji-Won Lee contributed equally to this paper. 
1Department of Family Medicine, Yonsei 
University College of Medicine, Seoul, Korea
2Biostatistics Collaboration Unit, 
Department of Research Affairs, Yonsei 
University College of Medicine, Seoul, Korea
3Department of Medicine, Graduate School, 
Yonsei University, Seoul, Korea
4Division of cardiology, Severance 
Cardiovascular Hospital, Yonsei University 
College of Medicine, Seoul, Korea
Correspondence
Da-Hye Son, MD, Assistant Clinical Research 
Professor, Department of Family Medicine, 
Yonsei University College of Medicine 
Gangnam Severance Hospital 211 Eonju-ro, 
Gangnam-gu, Seoul 135-720, Korea.
Email: sonda@yuhs.ac
Ji-Won Lee, MD, PhD, Associate Professor, 
Department of Family Medicine, Yonsei 
University College of Medicine Gangnam 
Severance Hospital 211 Eonju-ro, 
Gangnam-gu, Seoul, 135-720 Korea.
Email: indi5645@yuhs.ac
Funding information
This work was supported by the Technology 
Innovation Program (20002781, A Platform 
for Prediction and Management of Health 
Risk Based on Personal Big Data and 
Lifelogging) funded by the Ministry of Trade, 
Industry & Energy (MOTIE, Korea). This 
work was supported by the pilot study of 
the Korea National Health and Nutrition 
Examination Survey linked Cause of death 
data by the Korea Centers for Disease 
Control and Prevention.
Abstract
We investigated the relationship between blood pressure (BP) and mortality in pa-
tients taking antihypertensive medications in the Korean using data from the 2007-
2015 Korean National Health and Nutrition Examination Surveys. A total of 6601 
patients aged 30-74 years were included. Systolic BP (SBP) and diastolic BP (DBP) 
were both divided into four groups as follows: SBP < 120, 120 ≤ SBP ≤ 129 130 ≤ SB
P ≤ 139, and SBP ≥ 140; DBP < 70, 70 ≤ DBP ≤ 79, 80 ≤ DBP ≤ 89, and DBP ≥ 90. The 
survival rates and hazard ratios were evaluated using Kaplan-Meier curves and multi-
variable Cox regression analyses. To evaluate the predictability of all-cause mortality 
according to SBP and/or DBP, we calculated Harrell's concordance-index. The lowest 
DBP group had a high risk of mortality regardless of the SBP status. The group with 
DBP < 70 mm Hg and SBP ≥ 140 mm Hg showed the highest mortality. The discrimi-
natory ability calculated using Harrell's C-indexes was greater for the combination of 
SBP and DBP compared to DBP or SBP alone. These results suggest that it is more 
effective to simultaneously evaluate the effect of SBP and DBP to predict mortality; 
clinicians should manage DBP < 70 mm Hg when treating hypertensive patients.
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the target BP below 140/90 mm Hg.3 The JNC8 update in 2014 rec-
ommends a BP target < 150/90 mm Hg for people aged ≥ 60 years 
and maintained a target of 140/90 mm Hg for people < 60 years of 
age and patients with diabetes or chronic kidney disease.4 On the 
other hand, the 2017 American College of Cardiology/American Heart 
Association (ACC/AHA) Guideline updated the definition of hyperten-
sion as SBP/DBP > 130/80 mm Hg compared to a previous standard 
BP of 140/90 mm Hg.5 Based on the 2017 ACC/AHA guidelines, the 
prevalence of hypertension in the Korean population that requires 
antihypertensive medications was 44.8%, which was significantly in-
creased compared to the JNC7 prevalence of 18.4%.6 The Systolic 
Blood Pressure Intervention Trial and a meta-analysis demonstrated 
that intensive BP lowering reduced cardiovascular outcomes, and 
those results strongly contributed to changing BP thresholds in the 
2017 ACC/AHA guidelines.5,7 However, another meta-analysis re-
vealed that intensive BP lowering might be harmful in elderly people or 
people with diabetes.8 For these reasons, the 2018 European Society 
of Cardiology/European Society of Hypertension guideline maintained 
the definition of hypertension as >140/90 mm Hg and recommended 
antihypertensive medication targeting to <140/90 mm Hg.9
BP targets should be determined based on race- and coun-
try-specific risk factors. Considering the inconsistency in target 
BP values, a previous study suggested that the JNC7 target BP of 
140/90 mm Hg would be more appropriate than the 2017 ACC/AHA 
guideline in Korean populations based on all-cause mortality (ACM) 
and cardiovascular disease mortality.6 A few studies have been con-
ducted considering new guidelines of ideal BP control and mortality 
in patients taking antihypertensive medications. Furthermore, most 
recent investigations assessed the impact of SBP or DBP on clinical 
outcomes separately as opposed to simultaneously.10-12
The goal of this study was to clarify the relationship between 
ACM and SBP and DBP levels to identify optimal BP targets for pa-
tients taking antihypertensive medication. Additionally, we evalu-
ated the possible discriminatory ability of SBP and DBP for ACM in 




This study was conducted using data from the 2007-2015 Korean 
National Health and Nutrition Examination Survey (KNHANES) 
cohort provided by the Korea Centers for Disease Control and 
Prevention. KNHANES is a nationwide cross-sectional survey that 
represents the health and nutritional status of Koreans.13 We ob-
tained recent datasets containing any cause of death information. 
The study period was between January 1, 2007, and December 31, 
2015. From a pool of 43 156 participants aged 30-74 years, patients 
with any of the following criteria were excluded: history of stroke, 
acute MI, or any type of malignant cancer (n = 2452); death in the 
registration year (n = 41); no use of any antihypertensive medications 
(n = 30 134); and missing data of systolic BP (SBP), diastolic BP 
(DBP), or death (n = 3928). After exclusions, 6601 participants were 
analyzed (Figure 1).
2.2 | Data collection
A questionnaire was used to assess self-reported cigarette smok-
ing and alcohol consumption. Each participant was classified as a 
non-smoker, ex-smoker, or current smoker. Alcohol consumption 
was defined as drinking a certain quantity (≥7 drinks per time for 
males and ≥5 drinks per time for females) or frequency (≥2 times 
per week). BP was measured three times by qualified examiners at 
local examination centers, and the average of the second and third 
measurements was used.13 Body mass index (BMI) was calculated 
as the weight in kilograms divided by the square of the height in 
meters (kg/m2).
2.3 | Primary outcome
The end point of this study was ACM.
2.4 | Statistical analysis
The study population characteristics are presented as means ± stand-
ard deviations and frequencies (percentages). Both SBP and DBP were 
classified into four groups as follows: SBP < 120, 120 ≤ SBP ≤ 129, 
130 ≤ SBP ≤ 139, SBP ≥ 140; DBP < 70, 70 ≤ DBP ≤ 79, 80 ≤ DBP ≤ 89, 
DBP ≥ 90. Differences between groups were evaluated using one-
way analysis of variance (ANOVA) for continuous variables and chi-
square tests for categorical variables.
The survival rates for each group were evaluated using Kaplan-
Meier curves and log-rank tests. Incidences per 1000 person-years 
were calculated for each group. The hazard ratios (HRs) and 95% 
confidence intervals (CIs) with reference to the highest BP groups 
(SBP ≥ 140, DBP ≥ 90) were calculated by multivariable Cox regres-
sion analyses after adjusting for age, sex, and BMI. To evaluate the 
predictability of ACM according to SBP, DBP, and both SBP and DBP, 
we calculated Harrell's concordance (C)-indexes (95% CIs). To calcu-
late the 95% CIs and P-values for Harrell's C-index, we used a boot-
strap method and resampled 1000 times.
All statistical tests were performed using SAS software, version 
9.4 (SAS Institute Inc). All statistical analyses were two-sided, and 
P < .05 was considered statistically significant.
2.5 | Ethics statement
The study was approved by Yonsei University Health System's in-
stitutional review board (IRB number: 3-2018-0160), and informed 
consent was waived.
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3  | RESULTS
We analyzed data from 6601 adults, and 267 persons died during 
the study period (Figure 1). The study population characteristics 
according to BP criteria are shown in Table 1. Age showed a posi-
tive association with SBP and an inverse association with DBP. Total 
cholesterol, triglycerides, high-density lipoprotein cholesterol, and 
low-density lipoprotein cholesterol increased with higher SBP and 
DBP levels.
The cumulative incidence of ACM according to the SBP and 
DBP categories was assessed using Kaplan-Meier curves and log-
rank tests (Figure 2). A total of 2549 ACM events occurred during 
study period. There were no significant differences when compar-
ing ACM between SBP groups (overall P = .145). However, when 
comparing ACM between DBP groups regardless of SBP, we found 
that the cumulative incidence of ACM was highest in the lowest 
DBP group (DBP < 70). Within the group with SBP < 120, Group 1 
(DBP < 70) had a greater cumulative incidence of ACM than Group 
2 (70 ≤ DBP ≤ 79), Group 3 (80 ≤ DBP ≤ 89), and Group 4 (DBP ≥ 90). 
Subjects with SBP between 120 and 129 showed a similar pattern, 
where Group 1 was associated with a higher ACM incidence than 
Group 3 and 4. In groups with SBP between 130 and 139 and over 
140, the cumulative incidence of ACM was also found to be higher 
in Group 1 than in Group 4. When evaluating cumulative incidences 
of ACM between DBP groups within a fixed SBP category, we found 
that overall, the highest cumulative incidences of ACM was associ-
ated with subjects with the lowest DBP for any given SBP.
Table 2 presents the unadjusted incidences per 1000 per-
son-years and HRs for ACM based on group after adjusting 
for age, sex, and BMI. The group with DBP < 70 mm Hg and 
SBP ≥ 140 mm Hg showed the highest event rates for ACM per 
1000 person-years. For DBP analysis within the same SBP group, 
DBP < 70 had the highest incidence per 1000 person-year except 
in the SBP < 120 subgroup. There were no significant differences 
in HRs between SBP groups, whereas the HR (95% CI) of the low-
est DBP group was higher [2.439 (1.608-3.700)] than that of other 
DBP groups. DBP < 70 mm Hg was significantly associated with an 
increased risk of ACM in the SBP ≥ 130 group. This trend was simi-
lar in other groups with the exception of SBP < 120. The HRs (95% 
CIs) of the lowest DBP group were 3.224 (1.123-9.251) and 2.924 
(1.295-6.606) for the 130 ≤ SBP ≤ 139, and 140 ≤ SBP categories, 
respectively. Similar trend was remained even after additional ad-
justing of low-density lipoprotein cholesterol (LDL-C) and fasting 
glucose (Table S1).
Harrell's C-indexes were calculated to determine the possible 
discriminatory ability of SBP and/or DBP for ACM. DBP showed 
higher discrimination ability than SBP, but the combination had 
greater discrimination ability than DBP or SBP alone (Table 3).
Figure 3 shows the classification and regression tree (CART) 
analysis for considering the combined effects of SBP and DBP on the 
lowest mortality among patients taking antihypertensive medica-
tion. The cutoff DBP levels for predicting mortality were 70 mm Hg 
in the 120 ≤ SBP < 140 category and 80 mm Hg in the 140 ≤ SBP 
category.
F I G U R E  1   Study population flowchart diagram. CV, cardiovascular; DBP, diastolic blood pressure; HTN, hypertension; KNHANES, 
Korean National Health and Nutrition Examination Survey; MI, myocardial infarction; SBP, systolic blood pressure
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TA B L E  1   Clinical characteristics of the study population
SBP <120 (n = 1619) 120-129 (n = 1640) 130-139 (n = 1599) ≥140 (n = 1743) P-value
Age (y) 60.8 ± 9.1 60.4 ± 9.4 61.9 ± 8.7 63.5 ± 8.0 <.001
Female sex, n (%) 905 (55.9) 887 (54.1) 909 (56.9) 1093 (62.7) <.001
BMI, kg/m2 25.1 ± 3.3 25.4 ± 3.2 25.5 ± 3.3 25.3 ± 3.2 .004
Smokers, n (%) 646 (40.3) 666 (41.0) 616 (38.7) 582 (33.7) <.001
Alcohol drinkers, n (%) 552 (37.8) 594 (40.1) 556 (38.5) 521 (33.4) .001
SBP, mm Hg 111.3 ± 6.3 124.5 ± 2.9 134.2 ± 2.9 151.3 ± 11.0 <.001
DBP, mm Hg 72.0 ± 7.9 77.9 ± 8.5 81.4 ± 8.9 85.3 ± 11.1 <.001
Pulse rate 59.0 ± 12.9 56.8 ± 10.9 58.5 ± 12.1 58.5 ± 13.8 .511
Fasting Glucose, mg/dL 107.5 ± 29.1 107.4 ± 27.1 109.2 ± 31.3 109.3 ± 27.5 .107
HbA1c, mg/dL 6.3 ± 1.1 6.3 ± 1.1 6.3 ± 1.1 6.4 ± 1.1 .009
Insulin, mg/dL 11.0 ± 7.5 11.2 ± 8.7 11.3 ± 10.5 11.2 ± 8.8 .931
Total cholesterol, mg/dL 184.7 ± 35.4 187.4 ± 35.1 191.3 ± 37.5 194.8 ± 37.7 <.001
Triglycerides, mg/dL 148.7 ± 94.3 158.5 ± 99.7 164.7 ± 138.9 165.5 ± 123.7 <.001
HDL-C, mg/dL 46.1 ± 11.1 46.7 ± 11.0 47.2 ± 11.5 47.8 ± 11.5 <.001
LDL-C, mg/dL 108.9 ± 33.6 109.0 ± 33.9 111.1 ± 37.1 113.9 ± 37.0 <.001
AST, mg/dL 24.3 ± 11.5 24.9 ± 12.0 25.1 ± 14.5 25.1 ± 13.0 .285
ALT, mg/dL 23.7 ± 16.2 24.7 ± 15.4 24.3 ± 15.4 23.6 ± 14.9 .185
BUN, mg/dL 16.3 ± 5.2 16.2 ± 5.1 16.0 ± 5.4 16.3 ± 5.0 .201
Creatinine, mg/dL 0.9 ± 0.4 0.9 ± 0.4 0.9 ± 0.4 0.9 ± 0.3 .042
WBC, mg/dL 6.3 ± 1.7 6.3 ± 1.7 6.4 ± 1.8 6.4 ± 1.8 .360
DBP <70 (n = 1015) 70-79 (n = 2267) 80-89 (n = 2208) ≥90 (n = 1111) P-value
Age (y) 66.0 ± 7.1 63.5 ± 7.8 59.9 ± 9.1 57.3 ± 9.3 <.001
Female sex, n (%) 632 (62.3) 1353 (59.7) 1232 (55.8) 577 (51.9) <.001
BMI, kg/m2 24.6 ± 3.2 25.2 ± 3.2 25.5 ± 3.2 25.7 ± 3.3 <.001
Smokers, n (%) 367 (36.6) 821 (36.6) 853 (38.9) 469 (42.4) <.001
Alcohol drinkers, n (%) 263(28.8) 692 (33.8) 823 (41.1) 445 (45.3) <.001
SBP, mm Hg 119.7 ± 15.7 126.2 ± 13.9 133.1 ± 13.2 145.0 ± 15.2 <.001
DBP, mm Hg 63.5 ± 5.6 74.4 ± 3.0 83.6 ± 3.0 94.8 ± 5.6 <.001
Pulse rate 56.3 ± 10.8 58.9 ± 13.6 57.5 ± 10.8 63.0 ± 15.9 .005
Fasting glucose, mg/dL 114.4 ± 39.1 107.6 ± 25.9 106.9 ± 26.2 107.5 ± 27.8 <.001
HbA1c, mg/dL 6.5 ± 1.2 6.3 ± 1.0 6.3 ± 1.1 6.3 ± 1.1 <.001
Insulin, mg/dL 11.3 ± 12.3 11.0 ± 7.5 11.1 ± 9.3 11.6 ± 8.1 .608
Total cholesterol, mg/dL 182.3 ± 37.1 186.8 ± 35.6 191.7 ± 36.1 197.7 ± 37.5 <.001
Triglycerides, mg/dL 147.2 ± 85.6 149.0 ± 91.6 158.1 ± 99.7 193.6 ± 184.5 <.001
HDL-C, mg/dL 46.0 ± 11.3 46.6 ± 10.8 47.6 ± 11.6 47.2 ± 11.6 .001
LDL-C, mg/dL 106.9 ± 34.5 110.3 ± 33.4 112.4 ± 34.7 111.8 ± 41.4 <.001
AST, mg/dL 24.30 ± 12.9 24.0 ± 9.5 25.1 ± 12.9 26.6 ± 17.2 <.001
ALT, mg/dL 21.6 ± 14.0 22.9 ± 13.2 25.0 ± 16.4 26.8 ± 18.4 <.001
BUN, mg/dL 16.7 ± 6.0 16.4 ± 5.3 16.0 ± 4.8 15.7 ± 4.5 <.001
Creatinine, mg/dL 0.9 ± 0.6 0.9 ± 0.3 0.9 ± 0.3 0.9 ± 0.3 .009
WBC, mg/dL 6.4 ± 1.8 6.3 ± 1.8 6.3 ± 1.7 6.4 ± 1.7 .749
Note: Data are expressed as mean ± standard deviation or frequency (percentage). P-values were calculated using one-way ANOVA and chi-square 
tests.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate transaminase; BMI, body mass index; BUN, blood urea nitrogen; DBP, diastolic blood 
pressure; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood 
pressure; WBC, white blood cell.
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4  | DISCUSSION
It is important to manage hypertension to reduce the risk of car-
diovascular morbidity and mortality,5 but the treatment targets vary 
among different guidelines.5,9 Moreover, there is a paucity of studies 
on optimal BP targets in subjects taking antihypertensive medica-
tions. We investigated the optimal SBP and DBP levels to decrease 
ACM in patients taking antihypertensive medication.
Previous studies demonstrated that mortality was positively 
associated with the SBP level.3,14,15 However, we found that the 
highest cumulative incidences of ACM were associated with subjects 
with the lowest DBP for any given SBP. There were also no signifi-
cant differences in ACM according to SBP group in patients taking 
antihypertensive medication. Similar to our results, an analysis of the 
ONTARGET and TRASCEND trials showed increased risks of cardio-
vascular morbidity and mortality in DBP < 70 mm Hg compared with 
DBP 70-80 mm Hg. However, the study specified the medications 
(ramipril, telmisartan, and their combinations) and included patients 
aged ≥ 55 years without symptomatic heart failure at entry, and, 
with a history of coronary artery disease (CAD), peripheral artery 
F I G U R E  2   Kaplan-Meier curves and log-rank test for ACM according to BP levels. ACM, all-cause mortality; BP, blood pressure; DBP, 
diastolic blood pressure; SBP, systolic blood pressure
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disease, transient ischemic attack, stroke, or diabetes mellitus com-
plicated by organ damage.16 A cohort study of elderly subjects as-
sessed the risk of the cardiovascular outcomes of low DBP induced 
by antihypertensive medications.17 The authors found that reducing 
DBP below 60 mm Hg was associated with shorter survival indepen-
dent of large artery stiffness and left ventricle (LV) function. Based 
on this, they suggested an optimal DBP of 70 mm Hg for the elderly 
and suggested that physicians should also consider DBP in addition 
to SBP. Our findings also suggest that it is harmful to dramatically 
reduce DBP.
The mechanisms linking low DBP and higher mortality have 
not been fully understood, but there are plausible explanations. 
Coronary blood flow to the LV occurs in diastole. The pressure gra-
dient between the coronary arteries and the right atrium or LV in 
the diastolic phase is termed coronary perfusion pressure. If it de-
creases to 40-50 mm Hg, the effective flow becomes nearly zero, 
which can cause cessation of diastolic coronary arterial blood flow. 
Additionally, there is an autoregulatory system to compensate for 
obstructive conditions in the large proximal coronary artery. If it is 
narrowed by stenotic causes, dilatation of the smaller distal coro-
nary arteries occurs. This “autoregulation” helps ensure constant 
blood flow to the myocytes. In patients with CAD, a fall in DBP 
might reduce distal perfusion pressure, which prevents sufficient 
myocyte perfusion and can aggravate myocardial ischemia. This ex-
acerbation can increase LV filling pressures, perpetuating a vicious 
cycle by reducing the coronary perfusion pressure (pressure gradi-
ent). Left ventricular hypertrophy (LVH) impairs this autoregulatory 
mechanism. Patients with LVH may have sub-endocardial ischemia 
even in the absence of stenosis. This can trigger myocardial ischemia 




Incidence per 1000 
person-years (95% CI) HR (95% CI) Pairwise comparison P-value
SBP <120 1619 66 (4.1) 8.2 (6.2-10.1) 0.9 (0.7-1.3) .696 .146 .277
120-129 1640 56 (3.4) 6.6 (4.9-8.3) 0.8 (0.6-1.1) .128 .724 Ref
130-139 1599 57 (3.6) 6.6 (4.9-8.3) 0.7 (0.5-1.0) .055 Ref
≥140 1743 88 (5.1) 9.2 (7.3-11.1) 1 Ref
DBP <70 1015 63 (6.2) 13.7 (10.3-17.1) 2.4 (1.6-3.7) <.001 <.001 .001
70-79 2267 92 (4.1) 8.0(6.4-9.7) 1. 4 (0.9-2.0) .109 .108 Ref
80-89 2208 75 (3.4) 6.1 (4.7-7.5) 1.1 (0.7-1.6) .742 Ref
≥90 1111 37 (3.3) 5.8 (3.9-7.6) 1 Ref
SBP < 120 DBP < 70 544 33 (6.1) 12.9 (8.5-17.3) 0.7 (0.1-5.2) .718 .024 .013
70-79 777 25 (3.2) 6.4 (3.9-8.9) 0.4 (0.0-2.7) .315 .504 Ref
80-89 285 7 (2.5) 4.5 (1.2-7.9) 0.3 (0.0-2.2) .217 Ref
≥90 13 1 (7.7) 14.8 (14.0-43.5) 1 Ref
120-129 DBP < 70 222 14 (6.3) 14.9 (7.2-22.7) 3.4 (0.9-12.2) .064 <.001 .003
70-79 640 24 (3.8) 7.2 (4.3-10.0) 1.2 (0.3-4.0) .802 .265 Ref
80-89 650 15 (2.3) 4.3 (2.1-6.4) 0.8 (0.2-2.8) .722 Ref
≥90 128 3 (2.3) 4.6 (0.6-9.8) 1 Ref
130-139 DBP < 70 134 8 (6.0.) 13.0 (4.1-22.0) 3.2 (1.1-9.3) .030 .060 .166
70-79 480 18 (3.8) 7.6 (4.1-11.1) 1.8 (0.7-4.4) .210 .549 Ref
80-89 661 23 (3.5) 6.2 (3.6-8.7) 1.5 (0.6-3.5) .379 Ref
≥90 324 8 (2.5) 4.3 (1.3-7.2) 1 Ref
≥140 DBP < 70 115 8 (7.0) 16.3 (5.1-27.5) 2.9 (1.3-6.6) .010 .047 .414
70-79 370 25 (6.8) 14.0 (8.6-19.5) 2.1 (1.2-3.7) .011 .090 Ref
80-89 612 30 (4.9) 8.7 (5.6-11.8) 1.3 (0.8-2.3) .320 Ref
≥90 646 25 (3.9) 6.5 (4.0-9.1) 1 Ref
Abbreviations: ACM, all-cause mortality; CI, confidence interval; C-index: concordance-index; DBP, diastolic blood pressure; SBP, systolic blood 
pressure.






SBP 0.519 (0.491-0.551) Ref
DBP 0.584 (0.544-0.620) .030 Ref
Combination 0.611 (0.580-0.644) <.001 .024 Ref
Abbreviations: ACM, all-cause mortality; CI, confidence interval; 
C-index: concordance-index; DBP, diastolic blood pressure; SBP, 
systolic blood pressure.
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F I G U R E  3   CART analysis of the combined effects of SBP and DBP. CART, classification and regression tree; DBP, diastolic blood 
pressure; SBP, systolic blood pressure
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in patients with impaired coronary blood flow and concurrent LVH, 
even in a DBP range that is considered physiological.17-19 Secondly, 
low DBP and high pulse pressure might be an epiphenomenon of in-
creased arterial stiffness.17 An increased pulse wave velocity, which 
is an indicator of arterial stiffness, is highly associated with cardio-
vascular events.20 Blacher et al found that a pulse pressure that is 
10 mm wider increased the risk of cardiovascular events, irrespec-
tive of the SBP level.21
Another important finding in our study is that the discrimination 
ability for ACM using Harrell's C-indexes in patients using antihy-
pertensive medication. DBP has better discriminatory ability than 
SBP, but the combination of SBP and DBP showed better discrim-
inatory ability than DBP alone in patients taking antihypertensive 
medications.
Discrepant with our results, Hadaegh et al found that SBP had 
superior discrimination ability for cardiovascular disease mortality 
and ACM compared with other BP measures in an Iranian popula-
tion.22 However, the study excluded patients receiving antihyperten-
sive medications at baseline. Notably, few studies have considered 
both SBP and DBP levels.10-12 Large, longitudinal cohort studies are 
needed to confirm the influence of each BP measurement or the 
combined effect of SBP and DBP on mortality in patients taking an-
tihypertensive medications.
This study has several limitations. First, the sample size was 
small, and the total mortality was just 267 subjects. Among 267 
death subjects, cardiovascular death was only 62 (0.94%) and fatal 
death was 30 (0.45%). This made it difficult to evaluate mortalities 
attributed to cardiovascular diseases such as MI, hemorrhagic or 
ischemic stroke, or cardiovascular death. Second, since the data 
were originally collected using a cross-sectional design from 2007 
to 2015 and death information was added newly in 2018 after 
matching process, it was difficult to reveal the effect of BP control 
on all-cause mortality. In this regard, the effect of BP on clinical 
outcomes may be over- or underestimated due to confounding 
factors. Third, even though BP measurements were performed by 
qualified examiners using calibrated equipment, the lack of device 
uniformity and single-visit measurements might have introduced 
slight variations in our results. Large-scale long-term cohort stud-
ies are required and we plan to perform further study. Fourth, the 
population only included adults from Korea, so the findings might 
not be applicable to other races or ethnic groups. Fifth, these 
data do not contain information about the type of antihyperten-
sive agents used. Finally, we could not exclude the possibility of 
secondary hypertension due to lack of information. Despite these 
limitations, our study has several strengths. Most previous investi-
gations regarding the relationship between hypertension and mor-
talities were based on American or European populations.7,8,10 We 
used reliable nationwide data representing the health and nutri-
tional status of Koreans. Additionally, various statistical methods 
were employed to compensate for several biases and enhance the 
performance of predictive survival models using the combination 
of SBP and DBP.
5  | CONCLUSIONS
In conclusion, the cumulative incidence of ACM in patients taking 
antihypertensive medications was highest in the lowest DBP group 
(DBP < 70) regardless of SBP level. The combination of SBP and DBP 
has higher discrimination ability for ACM compared to SBP or DBP 
alone. Appropriate DBP cutoff levels for predicting mortality are 
70 mm Hg when 120 ≤ SBP < 140 and 80 mm Hg when 140 ≤ SBP. 
Therefore, clinical decisions for optimal BP with antihypertensive 
medications should simultaneously consider SBP and DBP levels 
and prevent DBP from falling below 70 mm Hg. Additional rand-
omized clinical studies are required to validate these results.
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